Argentus Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Argentus Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-41	Closed	-$3K	–	513
2016 Q3	$3K	Sell	41 -2,248	-98%	-$139K	﹤0.01%	558
2016 Q2	$124K	Buy	2,289 +2,279	+22,790%	+$125K	0.05%	362
2016 Q1	$1K	Sell	10 -80	-89%	-$4.16K	﹤0.01%	607
2015 Q4	$6K	Sell	90 -815	-90%	-$55.6K	﹤0.01%	515
2015 Q3	$56K	Buy	+905	New	+$71.3K	0.01%	466

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Argentus Capital Management's XBI Position: Q4 2016 in Review

Argentus Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2016, closing a stake of 41 shares — an estimated $3K sold.

Argentus Capital Management first reported a position in XBI in Q3 2015 and held it in 5 quarters. The position peaked at $124K in Q2 2016. 274 funds tracked by Wall St. Rank hold XBI as of Q4 2016.

Argentus Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2016 after selling out during the quarter.
Argentus Capital Management sold 41 State Street SPDR S&P Biotech ETF shares in Q4 2016, an estimated $3K.
Argentus Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and held it in 5 quarters.
Argentus Capital Management's State Street SPDR S&P Biotech ETF position peaked at $124K in Q2 2016.
274 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2016.

Based on Argentus Capital Management's 13F filing for Q4 2016.